I'm urging you to bring generic drug manufacturing back to the U.S. and stop relying on foreign factories that fail inspections. Please cosponsor the Scott-Gillibrand CLEAR LABELS Act, which passed committee 21-1, and support the Scott-Schiff bill to use Medicare's buying power for American-made generics.
Generics account for 91% of U.S. prescriptions, with about half from India, often using Chinese ingredients. In September 2025, FDA inspectors at Hetero, a major Indian HIV drug maker, were denied entry, and inside, inspection conditions were dire, with birds nesting above open drums and cats walking among pallets. A truck left uninspected. Inspectors had previously filmed staff shredding records. At Intas, hundreds of shredded bags were found at a plant supplying over half of the U.S. cisplatin and carboplatin. When it shut, 93% of cancer centers lacked enough carboplatin, leading the FDA to import Chinese cisplatin.
Americans are dying. Contaminated Indian eye drops killed four and blinded 14. Glenmark's recalled potassium chloride linked to at least eight U.S. deaths. ProPublica found the FDA quietly exempted over 20 banned factories, mostly in India, with drugs linked to hospitalizations and deaths.
Oversight is declining as risks grow. The FDA laid off over 3,500 staff in April 2025, including those handling foreign inspections, and stopped unannounced inspections in India. Before the cuts, only about 3% of Indian drug plants for the U.S. were inspected, while American plants remain underused.
I ask you to restore FDA's foreign inspection staff, end exemptions for banned factories unless independently tested, and fund long-term domestic production of essential medicines. Please share your position.
Sign Petition
